iQ&A Interactive Medical Intelligence Zone for Cancer and Thrombosis
iQ&A, The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behavior-changing information focused on critical and challenging topics in clinical medicine.
To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.
Questions reflecting the clinical needs of practitioners are then answered, analyzed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independently of commercial sources or the program sponsor.
The iQ&A platform stresses:
  • Needs assessment-driven CME content
  • Evidence-based analysis
  • Expert-based guidance and consultation
  • Compliance adherence
  • Independence of content generation
  • Landmark trials
  • Association-generated practice management guidelines
  • Quality of care improvement
  • Practice gap improvement
Intended Audience

  • Oncology specialists
  • Surgical oncology specialists
  • VTE and thrombosis specialists
  • Hematology/oncology specialists
  • Hospital pharmacists
  • Anticoagulation specialists
  • Hospitalists
  • Oncology nurses and NPs


Registration

Enrollment for this iQandA interactive Medical Intelligence Zone is complimentary, and clinicians are invited to participate in this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an independent educational grant from Eisai, Inc.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this educational activity for a maximum of 3.0 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the Postgraduate Institute of Medicine to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the Postgraduate Institute of Medicine are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Sam Schulman, MD
Chairman, Steering Committee/DSMB: Boehringer-Ingelheim, Bayer, AstraZeneca, sanofi-aventis, GlaxoSmithKline


Paul Ridker, MD
Consultant: AstraZeneca, Merck, Siemens, Isis
Grant/Researh Support: AstraZeneca, sanofi-aventis


Agnes Lee, MD
Consultant/Honoraria: Leo Pharma, Boehringer-Ingelheim, Bayer, Pfizer, sanofi-aventis
Grant/Research Support: Pfizer, Eisai


Clive Kearon, MD
Consultant: Boehringer-Ingelheim


Paul Stein, MD
Nothing to disclose


Craig Kessler, MD
Consultant: Eisai, sanofi-aventis
Grant/Research Support: Eisai, sanofi-aventis, GlaxoSmithKline
Stock Shareholder: Ibsen


Stavros Konstantinides, MD
Lecture fees: Bayer HealthCare, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, GlaxoSmithKline, sanofi-aventis


Robert Handin, MD
Nothing to disclose


Elaine Hylek, MD
Advisory Boards: Bristol-Myers Squibb, sanofi-aventis, Boehringer-Ingelheim


Jeff Weitz, MD
Consultant: Bristol-Myers Squibb,Pfizer, Boehringer-Ingelheim, Bayer, sanofi-aventis


Prof. Paolo Prandoni, MD
Nothing to disclose


Ajay Kakkar, MD
Consultant: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx
Grant/Research Support: Pfizer, Bristol-Myers, Squibb, sanofi0aventis, Boehringer-Ingelnheim, Bayer, GlaxoSmithKline, Eisai, Aryx


Prof. Sylvia Haas
Consultant: Boehringer-Ingelheim
Speaker’s Bureau: Boehringer-Ingelheim, Bayer
Grant/Research Support: sanofi-aventis


H. R. Buller, MD
Consultant: Bayer, GlaxoSmithKline, sanofi-aventis, Daiichi Sankyo, Pfizer, Isis
Grant/Research Support: Bayer, GlaxoSmithKline, sanofi-aventis, Daiichi Sankyo, Pfizer, Isis


Dr. A.G.G. Turpie
Consultant: Bayer, Johnson & Johnson, Pfizer, Astellas
Speaker’s Bureau: GlaxoSmithKline, Bayer Canada


Benjamin Brenner, MD
Grant/Research Support: sanofi-aventis


Frederick Rickles, MD
Consultant: Eisai Pharmaceuticals, Genmab, Pharmacyclics
Speaker’s Bureau: Eisai Pharmaceuticals


Henri Bounameaux, MD
Consultant: Bayer-Schering, Pfizer, sanofi-aventis, Boehringer-Ingelheim, Canon Pharma
Grant/Research Support: Bayer-Schering, Schering-Plough


John Alexander, MD
Research Support: Bristol Myers Squibb, Medtronic Japan, NIH, Portola Pharma, Regado Biosciences, Medicure, Millennium Pharmaceuticals, Momenta Pharma, Schering Plough
Consulting / Honorarium: Adolor, Astra Zeneca, Daiichi Sankyo, Medicure, NIH, Novartis, Pfizer


Charles Francis, MD
Consultant: Boehringer-Ingelheim
Grant/Research Support: Eisai


Giancarlo Agnelli, MD
Consultant: sanofi-aventis, Bayer, Boehringer-Ingelheim


Edith Nutescu, PharmD, FCCP
Consultant: Baxter
Speaker’s Bureau: Eisai
Grant/Research Support: Ortho McNeill Johnson


Michael Streiff, MD
Speaker’s Bureau: sanofi-aventis
Grant/Research Support: Bristol-Myers Squibb
Honoraria: sanofi-aventis, GlaxoSmithKline


Samuel Z. Goldhaber, MD
Grant/Research Support: AstraZeneca; Boehringer-Ingelheim; Eisai; GSK; sanofi-aventis;
Consultant: Boehringer-Ingelheim; BMS; Eisai; Merck; Pfizer; sanofi-aventis


Sunil Rao, MD
Consultant: sanofi-aventis, The Medicines Company, Cordis Corporation
Research funding: Cordis Corporation, Momenta Pharmaceuticals, Portola Pharmaceuticals


Richard Becker, MD
Grant/Research Support: Johnson & Johnson, Bristol-Myers Squibb, Bayer, Merck, Regado Biosciences


Deepak Bhatt, MD
Consultant: Arena, Astra Zeneca, Bristol-Myers Squibb, Cardax, Cogentus, Daiichi Sankyo, Eli Lilly, Eisai, Glaxo Smith Kline, Johnson & Johnson, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis, Schering Plough, Takeda, The Medicines Company, Vertex.
Principal Investigator for several potentially related studies. His institution has received funding from Bristol Myers Squibb, Eisai, Ethicon, Heartscape, sanofi-aventis, The Medicines Company.


William Geerts, MD
Consultant: Bayer, Boehringer-Ingelheim, Covidren
Honoraria: Bayer, Boehringer-Ingelheim, Pfizer, sanofi-aventis


Grants for educational activities and served as an advisor to GlaxoSmithKline, Medtronic, CV Therapeutics, The Medicines Company, sanofiaventis, Abbott, Boehringer Ingelheim, Pfizer and Eli Lilly and Company Grants for clinical research from Merck, Siemens, and Boston Scientific

Marco Valgimigli, MD, PhD
Senior Cardiologist
Department of Cardiology
University of Ferrara
Ferrara, Italy


Grants for clinical research from Merck.
Advisor or consultant for Medicines Company




Educational Objectives

Participants in this CME-certified iQandA will learn:
  • Apply NCCN, ASCO, and ACCP guidelines aimed at preventing primary and recurrent VTE in patients with cancer.
  • Assess patients with cancer, both in the inpatient and outpatient setting, and their likelihood for sustaining an initial or recurrent VTE; and, what the implications of their risk score is for prophylaxis management.
  • Compare the safety, efficacy, costs of monitoring, and long-term outcomes of vitamin K antagonists versus LMWHs when managing cancer patients who require secondary prevention of VTE.
  • Apply the results of landmark clinical trials in cancer and thrombosis to the front lines of oncology and surgical oncology care.
  • Explain the mechanisms of thrombosis formation in cancer and the effects of LWMHs on inhibition of the coagulation cascade and on angiogenesis.

Disclaimer

Copyright © 2009 by Pharmatecture, LLC and CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.
Copyright © CMEducation Resources, LLC and Pharmatecture, LLC